文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

局部复发前列腺癌挽救性立体定向体部放疗的前瞻性临床试验生活质量结果

Salvage Stereotactic Body Radiation Therapy for Locally Recurrent Prostate Cancer: Quality-of-Life Outcomes From a Prospective Clinical Trial.
PubMed 文献 · Pract Radiat Oncol · 2025-10-29

中位随访24个月,泌尿生殖毒性较胃肠道更常见,24个月G2+累积发生率分别为76.5%和29.4%,患者报告结局与不良事件一致,整体毒性及生活质量特征良好。

要点

  • 挽救性SBRT的24个月G2+泌尿生殖毒性累积发生率为76.5%,胃肠道为29.4%。
  • 泌尿生殖毒性高峰在12-15个月,与尿道再照射剂量关联最强。
  • 患者报告结局与不良事件一致,泌尿症状评分在3-18个月出现显著下降。

核心结论

  • 挽救性SBRT具有较好的治疗相关毒性和健康相关生活质量特征,毒性以泌尿生殖系统为主,并对应患者报告结局的下降。

主要发现

  • 24个月G2+不良事件累积发生率:泌尿生殖76.5%(95%CI,44.6%-90.0%),胃肠道29.4%(95%CI,4.1%-48.1%)。
  • 24个月G3+不良事件累积发生率:泌尿生殖11.8%(95%CI,0.0%-25.8%),胃肠道5.9%(95%CI,0.0%-16.4%)。
  • 泌尿生殖毒性在12至15个月达峰,与尿道再照射剂量关联最强。
  • 患者报告结局与不良事件一致:美国泌尿协会症状指数、EPIC泌尿刺激评分和EPIC泌尿失禁评分分别在3-6个月、6-9个月和9-18个月较基线有显著差异;胃肠道患者报告结局和PROMIS测量无显著差异。

关键数值与推荐

  • 挽救性SBRT剂量范围为40.0至42.5 Gy,靶区勾画由18F-DCFPyL PET/CT和MRI引导。
  • 不良事件采用NCI CTCAE v5.0评估,患者报告结局包括EPIC-26、AUA症状指数、SHIM、PROMIS焦虑、PROMIS抑郁和PROMIS心理社会疾病影响-积极量表。
  • 评估时间点为基线、1个月及SBRT后每3个月直至研究完成或生化失败。

临床怎么用

  • 对于前列腺癌局内复发患者,挽救性SBRT的毒性以泌尿生殖系统为主,需重点关注尿道再照射剂量。
  • 治疗后的泌尿生殖毒性高峰在12-15个月,随访中应结合患者报告结局动态评估症状。
  • 胃肠道毒性和PROMIS心理测量指标未见显著变化,支持该治疗在所选患者中具有较好的耐受性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Salvage stereotactic body radiation therapy (SBRT) for intraprostatic recurrence of prostate cancer is under study in early-phase clinical trials. Presently, the impact of this treatment on toxicity and health-related quality of life (HRQOL) is poorly defined. To our knowledge, we present the first report in the literature of HRQOL and psychometric outcomes from a mature, prospective clinical trial. METHODS AND MATERIALS: NCT03253744 was a phase 1 trial of focal salvage SBRT to doses of 40.0 to 42.5 Gy with target volume delineation guided by 18F-DCFPyL positron emission tomography/computed tomography and magnetic resonance imaging. Secondary endpoints included longitudinal assessment of National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 adverse events (AEs) and corresponding patient-reported outcome measures (PROMs). PROMs included the Expanded Prostate Cancer Inventory Composite (EPIC)-26, American Urologic Association Internal Prostate Symptom Score, Sexual Health Inventory for Men, Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety, PROMIS Depression, and PROMIS Psychosocial Illness Impact-Positive. Study assessments were conducted at baseline, 1 month, and at every 3-month interval post-SBRT until study completion or biochemical failure. RESULTS: Seventeen participants underwent salvage SBRT and were observed for a median of 24 months (min-max: 18-24 months). Toxicity assessment was completed in all participants, and the HRQOL response rate was 91%. Genitourinary (GU) toxicity was more common than gastrointestinal toxicity with a 24-month cumulative incidence of G2+ AEs of 76.5% (95% CI, 44.6%-90.0%) versus 29.4% (95% CI, 4.1%-48.1%) and G3+ AEs of 11.8% (95% CI, 0.0%-25.8%) versus 5.9% (0.0%-16.4%). GU toxicity peaked at 12 to 15 months and was associated most strongly with urethral reirradiation dose. PROMs were concordant with AEs, with significant differences from baseline noted in the American Urologic Association symptom index, EPIC GU irritation, and EPIC GU incontinence scores at 3 to 6 months, 6 to 9 months, and 9 to 18 months, respectively. No significant differences were noted in gastrointestinal PROMs or PROMIS measures. CONCLUSIONS: Salvage SBRT has a favorable treatment-related toxicity and HRQOL profile. Primarily, GU toxicities were observed corresponding to decrements in PROMs.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Patel KR, Schott E, Huang EP, et al. Salvage Stereotactic Body Radiation Therapy for Locally Recurrent Prostate Cancer: Quality-of-Life Outcomes From a Prospective Clinical Trial. Pract Radiat Oncol. 2025. PMID: 41173140. doi:10.1016/j.prro.2025.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。